First-in-Human Clinical Trials - What We Can Learn from Tragic Failures.

N Engl J Med

From the European Medicines Agency, London (S.B., G.R.); and the Second University of Naples, Naples (S.B.), and Istituto di Farmacologia Traslazionale del Consiglio Nazionale delle Ricerche (S.B.) and the University of Rome Tor Vergata (G.R.), Rome - all in Italy.

Published: November 2016

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMe1609006DOI Listing

Publication Analysis

Top Keywords

first-in-human clinical
4
clinical trials
4
trials learn
4
learn tragic
4
tragic failures
4
first-in-human
1
trials
1
learn
1
tragic
1
failures
1

Similar Publications

Homozygous MTAP deletion occurs in ~15% of cancers, making them vulnerable to decreases in the concentration of S-adenosylmethionine (SAM). AG-270/S095033 is an oral, potent, reversible inhibitor of methionine adenosyltransferase 2 A (MAT2A), the enzyme primarily responsible for the synthesis of SAM. We report results from the first-in-human, phase 1 trial of AG-270/S095033 as monotherapy in patients with advanced malignancies (ClinicalTrials.

View Article and Find Full Text PDF

Background: Peanut allergy (PA) is one of the most prevalent food allergies with a lack of favorable safety/efficacy treatment. A cucumber mosaic virus-like particle expressing peanut allergen component Ara h 2 (VLP Peanut) has been developed as a novel therapeutic approach for PA.

Objective: We assessed the tolerogenic properties and reactivity of VLP Peanut.

View Article and Find Full Text PDF

The role of genetic diversity, epigenetic regulation, and sex-based differences in HIV cure research: a comprehensive review.

Epigenetics Chromatin

January 2025

Department of Biomedical Sciences, Advanced Medical and Dental Institute, Universiti Sains Malaysia, Kepala Batas, Penang, Malaysia.

Despite significant advances in HIV treatment, a definitive cure remains elusive. The first-in-human clinical trial of Excision BioTherapeutics' CRISPR-based HIV cure, EBT-101, demonstrated safety but failed to prevent viral rebound. These outcomes may result from the interplay of several factors.

View Article and Find Full Text PDF

Background: Yttrium-90 FF-21101 (Y-FF-21101) is a radiopharmaceutical that targets P-cadherin as a therapy against solid tumors. A previously reported, first-in-human study determined that a dose of 25 mCi/m was safe, and a patient with clear cell carcinoma of the ovary achieved a complete response. In this article, the authors report the results of Y-FF-21101 treatment in an ovarian carcinoma expansion cohort and in patients with selected solid tumors who had known high P-cadherin expression.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!